BioSpace News Archive

Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that the U.S. Food and Drug Administration (FDA) has cleared Cellectis’ Investigational New Drug (IND) application to initiate a Phase 1/2a clinical trial of UCART20x22 for patients with relapsed or refractory Non-Hodgkin Lymphoma (r/r NHL).

ImmunoGen, Inc. announced that on July 29, 2022, the compensation committee of the Company’s Board of Directors approved grants of non-qualified stock option awards to purchase an aggregate of 667,800 shares of its common stock to sixteen new employees under the ImmunoGen, Inc. Inducement Equity Incentive Plan, as amended.

Cullinan Oncology, Inc. announced that the compensation committee of the Company’s Board of Directors granted stock option awards to purchase an aggregate of 137,700 shares of its common stock to four employees outside Cullinan Oncology, Inc’s 2021 Stock Option and Incentive Plan.

Breckenridge Pharmaceutical, Inc. announces today that the U.S. Food and Drug Administration has granted approval of its Abbreviated New Drug Application for Cabazitaxel Intravenous Powder (generic for Jevtana Kit®).

Encompass Health Corporation, the largest owner and operator of inpatient rehabilitation hospitals in the United States, reported its results of operations for the second quarter ended June 30, 2022 and affirmed its 2022 guidance.

Telix Pharmaceuticals Limited reports on regulatory progress for the Company’s core prostate and kidney cancer imaging programs in the Asia Pacific Operating Region, including progress in the major market of China with its strategic partner Grand Pharmaceutical Group Limited.

Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today that the Australian Patent Office (IP Australia) granted a notice of allowance to Biofrontera Bioscience GmbH for the patent “Photodynamic therapy comprising two light exposures at different wavelengths” (AU 2018/437303B2).

XVIVO Perfusion AB has signed an agreement to acquire 100 percent of the shares in Avionord S.r.l.'s machine and perfusion business for a purchase price amounting to a maximum of EUR 12.0 million.

Esperovax, a leading developer of oral mRNA biologics, and Life Magnetics, Inc., creators of RNA stabilization technology, today announced the signing of an agreement to co-develop an innovative new oral RNA therapeutic delivery system for colorectal cancer patients that can be stored at room temperature.

GC Biopharma (formerly known as Green Cross Corporation) (KRX: 006280), a South Korean biopharmaceutical company, today announced unaudited consolidated financial results for the three months ended 30 June 2022.